Targets › HA
2 programs from 2 companies in 2 trials: 2 Phase 1; Infectious disease, Vaccines; next expected readout Dec 2026.
Open in Phaseline: the race on HA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sanofi | Pandemic flu H5 HA mRNA SD2 vaccine mRNA vaccine encoding H5 hemagglutinin | HA | Phase 1 | Pandemic Influenza Immunization | Dec 2026 |
| National Institute of Allergy and Infectious Diseases (NIAID) | VRC-FLUMOS0122-00-VP (SteMos1) Quadrivalent influenza HA stem vaccine composed of pentameric scaffold with trimeric HA st | HA | Phase 1 | Influenza Prevention | Aug 2027 |
Influenza Prevention (1) Pandemic Influenza Immunization (1)
protein or peptide (1), other (1)
National Institute of Allergy and Infectious Diseases (NIAID) (1) Sanofi (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.